Protalix (PLX) AI Stock Analysis

• Market Cap: $126.77M
• Dividend Yield: N/A
• Average Volume (3M): 535.96K
• Price to Earnings (P/E): 20.8
• Beta (1Y): 0.71
• Revenue Growth: 62.79%
• EPS Growth: N/A
• Country: US
• Employees: 213
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): 0.00
• Shares Outstanding: 79,732,120
• 10 Day Avg. Volume: 577,633
• 30 Day Avg. Volume: 535,956
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.73
• Enterprise Value/Revenue: 1.49
• Enterprise Value/Gross Profit: 2.59
• Enterprise Value/Ebitda: 8.74
• 1Y Price Target: $15.00
• Price Target Upside: 874.03% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 62 Neutral
• Price Target: $1.50 ▼(-2.60% Downside)

Protalix's overall stock score is driven by significant improvements in financial performance and positive earnings call insights. However, technical indicators suggest potential bearish momentum, and valuation metrics indicate moderate attractiveness. The recent CFO appointment is a positive corporate event, contributing to a slightly higher score.

Positive Factors

Market Opportunity

Protalix management indicated that the total Fabry disease market opportunity may raise to $3.1B by 2030, with the potential for the royalty stream from Elfabrio to reach $120-150M per year to the company.

Product Approval

Pegunigalsidase alfa-iwxj is now approved across 23 territories globally for the treatment of Fabry disease.

Revenue Growth

Elfabrio royalty-based revenue rises, demonstrating demand.

Negative Factors

Revenue Miss

Protalix reported 1Q25 revenues from selling goods of $10M vs. forecast of $21.6M, attributed to choppiness in royalty-based revenue.

Revenue Uncertainty

Choppiness in royalty-based revenue impacted Protalix's financial performance, leading to a significant revenue miss against forecasts.

Protalix Business Overview & Revenue Model

Company Description

Protalix Biotherapeutics, Inc. (PLX) is a biopharmaceutical company focused on developing and commercializing innovative therapies for patients with debilitating and life-threatening diseases. The company specializes in the field of protein therapeutic products, leveraging its proprietary ProCellEx platform to produce biologics. Protalix's core products include Elelyso, an enzyme replacement therapy for Gaucher disease, and various other pipeline candidates targeting conditions such as Fabry disease and other metabolic disorders.

How the Company Makes Money

Protalix generates revenue primarily through the sale of its pharmaceutical products, particularly Elelyso, which is marketed in collaboration with Pfizer. The company also explores additional revenue streams through licensing agreements for its technologies and products, potential royalties from partners, and government grants for research and development. Key partnerships, such as those with Pfizer for distribution and marketing, significantly contribute to its earnings, while ongoing clinical trials and product development efforts aim to expand its portfolio and market presence.

Protalix Financial Statement Overview

Summary

Protalix has shown significant improvement in profitability and cash flow generation, crucial for financial stability. However, inconsistent revenue growth and high leverage remain concerns.

Income Statement

The company has demonstrated a positive turnaround in profitability over the last few years. Gross profit margins have been healthy, and there was a notable improvement in net income, moving from losses to profits recently. However, revenue growth has been inconsistent with a decline in the latest period, and EBIT margins are still relatively low, indicating room for operational improvements.

Balance Sheet

Protalix's balance sheet shows a significant reduction in total debt, which is a positive sign for financial health. The equity position has improved from negative to positive, enhancing the equity ratio. However, the debt-to-equity ratio is still high, indicating potential leverage risks. The company needs to continue strengthening its equity to mitigate these risks further.

Cash Flow

The company has shown a strong improvement in cash flow, moving from negative free cash flow to positive in the latest period. The operating cash flow to net income ratio indicates a healthy conversion of profits into cash. However, the free cash flow growth rate is volatile, suggesting potential fluctuations in cash generation capabilities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	61.95M	53.40M	65.49M	47.64M	38.35M	62.90M
Gross Profit	35.64M	29.08M	42.51M	28.05M	22.00M	52.02M
EBITDA	10.55M	6.52M	12.94M	-10.78M	-18.94M	4.45M
Net Income	6.28M	2.93M	8.31M	-14.93M	-27.58M	-6.52M
Balance Sheet
Total Assets	78.49M	73.42M	84.43M	55.79M	73.67M	67.93M
Cash, Cash Equivalents and Short-Term Investments	33.40M	34.83M	44.56M	22.18M	38.98M	38.55M
Total Debt	5.35M	5.53M	26.28M	33.47M	33.47M	64.40M
Total Liabilities	28.58M	30.21M	50.87M	66.43M	79.70M	94.97M
Stockholders Equity	49.90M	43.21M	33.57M	-10.64M	-6.04M	-27.04M
Cash Flow
Free Cash Flow	-3.44M	7.39M	-2.47M	-25.63M	-11.74M	-26.76M
Operating Cash Flow	-2.19M	8.67M	-1.32M	-25.00M	-10.29M	-26.11M
Investing Cash Flow	4.26M	4.22M	-16.71M	-5.04M	18.92M	-19.95M
Financing Cash Flow	-7.61M	-16.79M	24.67M	8.24M	12.08M	46.47M

Protalix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.54
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PLX, the sentiment is Negative. The current price of 1.54 is below the 20-day moving average (MA) of 1.58, above the 50-day MA of 1.52, and below the 200-day MA of 1.98, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 47.91 is Neutral, neither overbought nor oversold. The STOCH value of 33.93 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PLX.

Protalix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PLX	62 Neutral	$126.77M	20.81	15.99%	―	62.79%	―
LXRX	61 Neutral	$388.84M	―	-65.30%	―	1504.83%	56.81%
Sector *	51 Neutral	$7.95B	-0.40	-41.67%	2.21%	22.29%	-1.85%
DBVT	48 Neutral	$251.94M	―	-148.73%	―	―	-22.49%
TERN	45 Neutral	$631.83M	―	-35.02%	―	―	20.37%
HURA	36 Underperform	$127.62M	―	-287.92%	―	―	97.61%
GOSS	35 Underperform	$570.73M	―	-783.37%	―	-58.02%	-57.23%

Protalix Corporate Events

Protalix Amends Market Offering Agreement with H.C. Wainwright

On August 22, 2025, Protalix BioTherapeutics, Inc. amended its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, allowing the company to offer and sell shares of its common stock through an equity offering program. This amendment aligns with the company’s new registration statement, potentially impacting its market operations and stakeholder interests.

Protalix Lawsuit Dismissed After Bylaws Amendment

On August 1, 2025, Protalix BioTherapeutics, Inc. announced the dismissal of a class action lawsuit filed by Kevin Mathew Thomas against the company and its Board of Directors. The lawsuit, filed on March 10, 2025, alleged violations in the company’s bylaws. The company denied all allegations but amended the bylaws on May 8, 2025, leading to the plaintiff agreeing that the claims were moot. Consequently, the company agreed to pay $160,000 in fees and expenses to the plaintiff’s counsel, and the case was dismissed with prejudice on July 23, 2025.

Protalix Appoints New CFO to Boost Growth Strategy

On July 21, 2025, Protalix BioTherapeutics announced the appointment of Gilad Mamlok as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. Mamlok, with three decades of experience in healthcare and technology sectors, is expected to play a crucial role in executing Protalix’s growth strategy. The transition is designed to be seamless with Rubin assisting until October 2025. This leadership change is anticipated to strengthen Protalix’s financial and operational strategies, further solidifying its position in the biopharmaceutical industry.

Protalix Holds Annual Stockholders Meeting in Tel Aviv

On June 26, 2025, Protalix Biotherapeutics, Inc. held its Annual Meeting of Stockholders in Tel Aviv, Israel. During the meeting, stockholders elected eight board members, approved executive compensation on a non-binding basis, and ratified the appointment of Kesselman & Kesselman as the independent accounting firm for the fiscal year ending December 31, 2025.